(Q51309944)

English

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.

scientific article published on 17 September 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

chronic phase chronic myelogenous leukemia

0 references

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

François Guilhot

object named as

François Guilhot

11

0 references

author name string

Philippe Rousselot

1

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Pascale Cony-Makhoul

2

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Franck Nicolini

3

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

François Xavier Mahon

4

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Christian Berthou

5

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Josy Reiffers

7

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Anne Bornand

8

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Olivier Saint-Jean

9

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Joelle Guilhot

10

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

French Intergroup For Chronic Myelogenous Leukemia (Fi-LMC)

12

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

publication date

17 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

88

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

1

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

1-4

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

Epidemiology of chronic myeloid leukaemia (CML).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

How long will chronic myeloid leukemia patients treated with imatinib mesylate live?

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23330

21 January 2018

Identifiers

10.1002/AJH.23330

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

release_rhmhv4pnjzdopdngiem3ftv5jy

1 reference

https://api.fatcat.wiki/v0/release/rhmhv4pnjzdopdngiem3ftv5jy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22987312

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51309944&oldid=1843546442"